Recent Advances in Pyrazole-Based Protein Kinase Inhibitors as Emerging Therapeutic Targets

dc.contributor.author Cetin, Adnan
dc.date.accessioned 2025-05-10T17:34:43Z
dc.date.available 2025-05-10T17:34:43Z
dc.date.issued 2024
dc.description Cetin, Adnan/0000-0003-4838-1503 en_US
dc.description.abstract Background Pyrazole-scaffold protein kinase inhibitors (PKIs) have emerged as promising therapeutic agents for the treatment of various diseases, such as cancer, inflammatory disorders, and neurological diseases. This review article provides an overview of the pharmacological properties of pyrazole-scaffold PKIs, including their mechanism of action, selectivity, potency, and toxicity. The article also summarizes the recent developments in the design and synthesis of pyrazole-scaffold PKIs, highlighting the structural features and modifications that contribute to their pharmacological activity. In addition, the article discusses the preclinical and clinical studies of pyrazole-scaffold PKIs, including their efficacy, safety, and pharmacokinetic properties.Methods A comprehensive search has been conducted on several online patent databases, including the United States Patent and Trademark Office (USPTO), the European Patent Office (EPO), and the World Intellectual Property Organization (WIPO). The search was conducted using pyrazole as the keyword. The search was limited to patents filed between 2015 and 2022. Patents were included if they involved articles in the fields of protein kinase inhibitors, and included literature on some pyrazoles and their pharmacological activities.Results Data were extracted from each included patent on the following variables: patent title, patent number, inventors, assignee, filing date, publication date, patent type, and field of invention. Data were extracted from each patent using a standardized form to ensure consistency and accuracy.Conclusion The design and pharmacological evaluation of organic compounds containing pyrazole structure as biologically active substances have been done, and the key structures from the pharmacological data obtained as protein kinase inhibitors have been addressed in detail. The review concludes with a discussion on the current challenges and future directions for the development of pyrazole-scaffold PKIs as therapeutic agents. Overall, this review article provides a comprehensive summary of the pharmacological properties of pyrazole-scaffold PKIs, which will be of interest to researchers and clinicians in the field of drug discovery and development. en_US
dc.identifier.doi 10.2174/0113862073252211231024182817
dc.identifier.issn 1386-2073
dc.identifier.issn 1875-5402
dc.identifier.scopus 2-s2.0-85201674637
dc.identifier.uri https://doi.org/10.2174/0113862073252211231024182817
dc.identifier.uri https://hdl.handle.net/20.500.14720/13899
dc.language.iso en en_US
dc.publisher Bentham Science Publ Ltd en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Cancer en_US
dc.subject Drug Discovery en_US
dc.subject Pharmacology en_US
dc.subject Spectroscopy en_US
dc.subject Pyrazole-Based Protein Kinase Inhibitors en_US
dc.subject Therapeutic Targets en_US
dc.title Recent Advances in Pyrazole-Based Protein Kinase Inhibitors as Emerging Therapeutic Targets en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Cetin, Adnan/0000-0003-4838-1503
gdc.author.institutional Cetin, Adnan
gdc.author.scopusid 24586619800
gdc.author.wosid Cetin, Adnan/Adp-4852-2022
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.description.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
gdc.description.departmenttemp [Cetin, Adnan] Van Yuzuncu Yil Univ, Fac Educ, Dept Chem, TR-65080 Van, Turkiye en_US
gdc.description.endpage 2804 en_US
gdc.description.issue 19 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.startpage 2791 en_US
gdc.description.volume 27 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q3
gdc.identifier.pmid 37946345
gdc.identifier.wos WOS:001335747300015
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed

Files